Free Trial
→ From the man who predicted 2008 crash… (From Porter & Company) (Ad)tc pixel
NASDAQ:ELAB

PMGC 5/14/2025 Earnings Report

PMGC logo
$2.22 +0.24 (+12.12%)
As of 12:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

PMGC EPS Results

Actual EPS
-$243.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PMGC Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PMGC Announcement Details

Quarter
Date
5/14/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

PMGC Earnings Headlines

PMGC Holdings Completes Acquisition of A&B Aerospace Business
May 13 at 6:51 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/pmgc-holdings-completes-acquisition-of-ab-aerospace-business?utm_source=marketbeat.com&utm_medium=referral
PMGC Holdings Inc. Acquires A&B Aerospace to Strengthen Precision Manufacturing Platform in Aerospace and Defense Industry
May 13 at 4:11 AM  |  quiverquant.comQ
Read this or regret it forever
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.tc pixel
May 14 at 1:00 AM  |  Porter & Company (Ad)
PMGC Holdings (NASDAQ: ELAB) Acquires A&B Aerospace, Inc.
May 13 at 4:03 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/13/3293695/0/en/pmgc-holdings-nasdaq-elab-acquires-a-b-aerospace-inc.html
UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use ...
April 29, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/updated-northstrive-biosciences-files-new-u-s-patent-application-covering-el-22-formulations-and-dosing-for-treatment-of-muscle-wasting-conditions-related-to-glp-1-use-sarcopenia-muscle-disuse-1036073898
UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atrophy, and Certain Neurological Disorders
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3283157/0/en/updated-northstrive-biosciences-files-new-u-s-patent-application-covering-el-22-formulations-and-dosing-for-treatment-of-muscle-wasting-conditions-related-to-glp-1-use-sarcopenia-m.html
See More PMGC Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PMGC? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PMGC and other key companies, straight to your email.

About PMGC

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.

View PMGC Profile
Earnings Tools